Monte Rosa Therapeutics, Inc. Quarterly Depreciation in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Monte Rosa Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q1 2021 to Q3 2024.
  • Monte Rosa Therapeutics, Inc. Depreciation for the quarter ending September 30, 2024 was $2.1M, a 14.7% increase year-over-year.
  • Monte Rosa Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2024 was $7.91M, a 45.2% increase year-over-year.
  • Monte Rosa Therapeutics, Inc. annual Depreciation for 2023 was $6.22M, a 66.1% increase from 2022.
  • Monte Rosa Therapeutics, Inc. annual Depreciation for 2022 was $3.75M, a 75.7% increase from 2021.
  • Monte Rosa Therapeutics, Inc. annual Depreciation for 2021 was $2.13M, a 297% increase from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $7.91M $2.1M +$269K +14.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $7.64M $2.06M +$669K +48.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $6.97M $1.9M +$746K +64.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $6.22M $1.85M +$776K +72.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $5.45M $1.83M +$801K +77.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $4.65M $1.39M +$502K +56.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $4.14M $1.15M +$398K +52.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $3.75M $1.07M +$212K +24.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $3.53M $1.03M +$433K +72.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.1M $889K +$489K +122% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $2.61M $753K +$479K +175% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $2.13M $858K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $600K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $400K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $274K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.